-
Thematic Analysis
NewPharma M&A Deals Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Pharma Sector
-
Thematic Analysis
NewGlobal M&A Deals in Q1 2024 – Top Themes by Sector – Thematic intelligence
The global M&A market in Q1 2024 witnessed deals worth $613 billion, a rise of 38% compared to Q1 2024. In terms of deal volume, there was a 13% fall from 8,468 deals in Q1 2023 to 7,248 M&A deals in Q1 2024. The TMT sector led the M&A deal activity, with 2,163 deals worth $186 billion recorded in Q1 2024. Most sectors saw a year-on-year increase in deal activity in Q1 2024. Mega-deals (defined as any deal valued at...
-
Product Insights
NewNet Present Value Model: Altimmune Inc’s Pemvidutide
Empower your strategies with our Net Present Value Model: Altimmune Inc's Pemvidutide report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of CymaBay Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CymaBay Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Seladelpar Lysine in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Seladelpar Lysine in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Seladelpar Lysine in Primary Biliary Cholangitis...
-
Product Insights
Primary Sclerosing Cholangitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Sclerosing Cholangitis - Drugs In Development, 2023’, provides an overview of the Primary Sclerosing Cholangitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Drugs In Development, 2023’, provides an overview of the Primary Biliary Cholangitis (Primary Biliary Cirrhosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Cholangitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cholangitis - Drugs In Development, 2023’, provides an overview of the Cholangitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Liver Cirrhosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Liver Cirrhosis - Drugs In Development, 2023’, provides an overview of the Liver Cirrhosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Company Profile
CymaBay Therapeutics Inc – Company Profile
CymaBay Therapeutics Inc (CymaBay), formerly Metabolex Inc is a clinical-stage biopharmaceutical company that develops therapeutics to treat diabetes, liver and other chronic diseases, orphan diseases and related metabolic disorders. The company’s pipeline products comprise Seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd) for the treatment of liver diseases. It also develops MBX-2982 for patients with type 1 diabetes, orphan indications and for various diseases affecting liver functions. The company has collaboration with various pharmaceutical...
Add to Basket